Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 199 Breast Neoplasms 111 Carcinoma, Non-Small-Cell Lung 94 Triple Negative Breast Neoplasms 66 Neoplasm Metastasis 44 Neoplasms 42 Lung Neoplasms 25 Squamous Cell Carcinoma of Head and Neck 24 Colorectal Neoplasms 18 Stomach Neoplasms 17 Esophageal Squamous Cell Carcinoma 17 Adenocarcinoma 17 Melanoma 15 Head and Neck Neoplasms 15 Ovarian Neoplasms 12 Cholangiocarcinoma 11 Carcinoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Gallbladder Neoplasms 10 Esophageal Neoplasms 10 Carcinoma, Pancreatic Ductal 10 Small Cell Lung Carcinoma 9 Sarcoma 9 Fallopian Tube Neoplasms 9 Biliary Tract Neoplasms 9 Carcinoma, Squamous Cell 8 Neoplasms by Site 7 Pancreatic Diseases 6 Pancreatic Adenocarcinoma 6 Digestive System Neoplasms 6

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × 130-nm albumin-bound paclitaxel × Clear all

NCT04876313 2022-04-06

NURE-Combo

IRCCS San Raffaele

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡